Molecular and clinical implementations of ovarian cancer mouse avatar models

Chinese Clinical Oncology

Volumn 4, Issue 3, 2015, Pages

  Zayed, Amira A ^a   Mandrekar, Sumithra J ^a   Haluska, Paul ^a  

^a MAYO CLINIC   (United States)

Author keywords

Clinical trial design; Model systems; Ovarian cancer (OC); Patient derived xenografts (PDX); Personalized medicine; Xenograft models

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM;

CANCER MODEL; CANCER RESISTANCE; CANCER TRANSPLANTATION; CARCINOGENESIS; DRUG EFFICACY; GRAFT FAILURE; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; LYMPHOMA; METASTASIS; MOLECULAR PATHOLOGY; MOUSE MODEL; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; OVARY CANCER; PERSONALIZED MEDICINE; PRECLINICAL STUDY; REVIEW; TIME; TREATMENT RESPONSE; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG SCREENING; FEMALE; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MOUSE; OVARY TUMOR; PATHOLOGY; PROCEDURES;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; FEMALE; HUMANS; MICE; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; PRECISION MEDICINE; RESEARCH DESIGN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84960393736     PISSN: 23043865     EISSN: 23043873     Source Type: Journal    
DOI: 10.3978/j.issn.2304-3865.2015.04.01     Document Type: Review

References (57)

1. Cancer Facts & Figures. Available online: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/
2. van Dalen A, Favier J, Burges A, et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000;79:444-50.
3. Hutchinson L, Kirk R. High drug attrition rates-where are we going wrong? Nat Rev Clin Oncol 2011;8:189-90.
4. Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer. Lancet 2014;384:1376-88.
5. Gillet JP, Calcagno AM, Varma S, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A 2011;108:18708-13.
6. Weroha SJ, Becker MA, Enderica-Gonzalez S, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res 2014;20:1288-97.
7. Elkas JC, Baldwin RL, Pegram M, et al. A human ovarian carcinoma murine xenograft model useful for preclinical trials. Gynecol Oncol 2002;87:200-6.
8. Topp MD, Hartley L, Cook M, et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol 2014;8:656-68.
9. Singh S, Ross SR, Acena M, et al. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med 1992;175:139-46.
10. Ochsenbein AF, Klenerman P, Karrer U, et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 1999;96:2233-8.
11. Zhang B, Bowerman NA, Salama JK, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 2007;204:49-55.
12. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-48.
13. Bombara MP, Webb DL, Conrad P, et al. Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines. J Leukoc Biol 1993;54:399-406.
14. Nazareth MR, Broderick L, Simpson-Abelson MR, et al. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol 2007;178:5552-62.
15. Barnas JL, Simpson-Abelson MR, Brooks SP, et al. Reciprocal functional modulation of the activation of T lymphocytes and fibroblasts derived from human solid tumors. J Immunol 2010;185:2681-92.
16. Allen M, Louise Jones J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 2011;223:162-76.
17. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27:5904-12.
18. Simpson-Abelson MR, Sonnenberg GF, Takita H, et al. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. J Immunol 2008;180:7009-18.
19. Lee CH, Xue H, Sutcliffe M, et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 2005;96:48-55.
20. Press JZ, Kenyon JA, Xue H, et al. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol 2008;110:256-64.
21. Erez N, Truitt M, Olson P, et al. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell 2010;17:135-47.
22. Auersperg N, Wong AS, Choi KC, et al. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88.
23. Kaneko T, Saito H, Toya M, et al. Hyaluronic acid inhibits apoptosis in granulosa cells via CD44. J Assist Reprod Genet 2000;17:162-7.
24. Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190-8.
25. Sale S, Orsulic S. Models of ovarian cancer metastasis: Murine models. Drug Discov Today Dis Models 2006;3:149-154.
26. Hunter KW. Host genetics and tumour metastasis. Br J Cancer 2004;90:752-5.
27. Cheon DJ, Orsulic S. Mouse models of cancer. Annu Rev Pathol 2011;6:95-119.
28. Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech 2008;1:78-82.
29. McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. Clin Cancer Res 2009;15:1898-905.
30. Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012;9:338-50.
31. van der Meel R, Gallagher WM, Oliveira S, et al. Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. Drug Discov Today 2010;15:102-14.
32. Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014;4:998-1013.
33. Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004;40:827-36.
34. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:852-61.
35. Vidal A, Muñoz C, Guillén MJ, et al. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res 2012;18:5399-411.
36. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-5.
37. An MW, Mandrekar SJ, Sargent DJ. A 2-stage phase II design with direct assignment option in stage II for initial marker validation. Clin Cancer Res 2012;18:4225-33.
38. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-34.
39. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010;102:152-60.
40. Sargent DJ, Conley BA, Allegra C, et al. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23:2020-7.
41. Cree IA, Kurbacher CM, Lamont A, et al. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 2007;18:1093-101.
42. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998-2006.
43. Mandrekar SJ, An MW, Sargent DJ. A review of phase II trial designs for initial marker validation. Contemp Clin Trials 2013;36:597-604.
44. Maykel J, Liu JH, Li H, et al. NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl): a model for stromal cell-tumor cell interaction for human colon cancer. Dig Dis Sci 2014;59:1169-79.
45. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013;501:346-54.
46. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429-47.
47. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
48. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-7.
49. Chen K, Ahmed S, Adeyi O, et al. Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus. PLoS One 2012;7:e39294.
50. Custer RP, Bosma GC, Bosma MJ. Severe combined immunodeficiency (SCID) in the mouse. Pathology, reconstitution, neoplasms. Am J Pathol 1985;120:464-77.
51. Clinical Trials Recruitment and Enrollment: Attitudes, Barriers, and Motivating Factors. Available online: http://cro.rbhs.rutgers.edu/documents/clinical_trials_recruitment_and_enrollment.pdf
52. Frank G. Current challenges in clinical trial patient recruitment and enrollment. SoCRA Source 2004:30-8.
53. Lee EC, Liang Q, Ali H, et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat Biotechnol 2014;32:356-63.
54. Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A 2014;111:5147-52.
55. Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A 2014;111:5153-8.
56. Rongvaux A, Willinger T, Martinek J, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 2014;32:364-72.
57. Kalscheuer H, Danzl N, Onoe T, et al. A model for personalized in vivo analysis of human immune responsiveness. Sci Transl Med 2012;4:125ra30.